Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAN: Ramucirumab, Atezolizumab and N-803 in NSCLC
NCT05007769Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2021
- Primary completion
- Apr 2024
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
01
Overview
A Phase 2 trial of ramucirumab, nogapendekin alfa inbakicept in non-small cell lung cancer (NSCLC), sponsored by Washington University School of Medicine. Planned start Oct 2021; status: withdrawn.
02
Drugs
ramucirumabnogapendekin alfa inbakicept
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05007769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007769.